Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

NCT02675959 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

New York Medical College

Collaborators